NeuroMetrix, Inc.
Jun 26, 2017

NeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data Scientist

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its data science initiative and the related Quell® Health Cloud.

Data science consists of the development of large cloud databases and the use of powerful analytical tools such as machine learning and artificial intelligence. The Quell device and its companion smartphone app connect seamlessly with the Quell Health Cloud. The cloud database stores the user's demographic and clinical profile, health metrics including pain, sleep, activity and gait, and device utilization. The Quell Health Cloud has over thirty thousand registered Quell users, and growing. It is one of the largest chronic pain databases in the world. Initial research findings have already been presented at several scientific meetings and the Company expects to report additional results at clinical and connected health meetings over the next year.

In connection with the Company's expanding data science initiative, Dr. Xuan Kong has been promoted to Chief Data Scientist. Dr. Kong has been with NeuroMetrix for nearly 20 years, most recently as SVP of Research and Intellectual Property. Dr. Kong has a broad background and experience base that encompasses data analytics, engineering, neurophysiology and business. He holds a PhD in Electrical Engineering from Johns Hopkins University and an MBA from Boston University.

"Chronic pain is a complex biopsychosocial condition that requires a customized treatment approach. Our vision is to leverage the unique data assets we are collecting in the Quell Health Cloud to deliver personalized pain relief for our customers," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "I am looking forward to Xuan's leadership in executing on this vision with his deep technical and product development expertise."

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media